主观认知下降的ATN分类与临床进展:SCIENCe项目
本研究在693例主观认知下降(SCD)者中按ATN模型分类,其中342例有随访(3±2年)。与A-T-N-相比,A+谱者痴呆风险更高且记忆、注意、语言及执行功能下降更陡;对照组无此关联。提示生物标志物可用于个体化风险分层。
要点
- SCD人群中A+谱者较A-T-N-者痴呆风险升高,且呈生物标志物数量剂量反应。
- A+谱者在记忆、注意、语言及执行功能测试中下降更陡。
- 无SCD对照组中ATN与认知无关联。
核心结论
- 在记忆门诊SCD者中,A-T+N+、A+T-N-、A+T+N-和A+T+N+谱者较A-T-N-者痴呆风险增加且认知下降更陡。
研究设计与样本
- 纳入693例SCD者(60±9岁,41%女性,MMSE 28±2),按淀粉样PET或脑脊液β-淀粉样蛋白、脑脊液p-tau及MRI内侧颞叶萎缩进行ATN分类,342例有随访(3±2年),并设124例无SCD对照。
主要发现
- Cox回归显示A+谱者较A-T-N-者痴呆风险更高,且随受累生物标志物数量呈剂量反应模式。
- 线性混合模型显示A+谱者在记忆、注意、语言及执行功能测试中下降更陡。
- 对照组中ATN与认知无关联。
临床怎么用
- 对记忆门诊的SCD者,ATN生物标志物分型可用于个体化痴呆风险分层。
局限性
- 仅342例有随访,随访时间3±2年。
- A-T+N+、A+T-N+和A+T+N+谱者数量很少。
- 对照人群仅124例且无SCD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the relationship between the ATN classification system (amyloid, tau, neurodegeneration) and risk of dementia and cognitive decline in individuals with subjective cognitive decline (SCD). METHODS: We classified 693 participants with SCD (60 ± 9 years, 41% women, Mini-Mental State Examination score 28 ± 2) from the Amsterdam Dementia Cohort and Subjective Cognitive Impairment Cohort (SCIENCe) project according to the ATN model, as determined by amyloid PET or CSF β-amyloid (A), CSF p-tau (T), and MRI-based medial temporal lobe atrophy (N). All underwent extensive neuropsychological assessment. For 342 participants, follow-up was available (3 ± 2 years). As a control population, we included 124 participants without SCD. RESULTS: Fifty-six (n = 385) participants had normal Alzheimer disease (AD) biomarkers (A-T-N-), 27% (n = 186) had non-AD pathologic change (A-T-N+, A-T+N-, A-T+N+), 18% (n = 122) fell within the Alzheimer continuum (A+T-N-, A+T-N+, A+T+N-, A+T+N+). ATN profiles were unevenly distributed, with A-T+N+, A+T-N+, and A+T+N+ containing very few participants. Cox regression showed that compared to A-T-N-, participants in A+ profiles had a higher risk of dementia with a dose-response pattern for number of biomarkers affected. Linear mixed models showed participants in A+ profiles showed a steeper decline on tests addressing memory, attention, language, and executive functions. In the control group, there was no association between ATN and cognition. CONCLUSIONS: Among individuals presenting with SCD at a memory clinic, those with a biomarker profile A-T+N+, A+T-N-, A+T+N-, and A+T+N+ were at increased risk of dementia, and showed steeper cognitive decline compared to A-T-N- individuals. These results suggest a future where biomarker results could be used for individualized risk profiling in cognitively normal individuals presenting at a memory clinic.
引用
- Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020. PMID: 32522798. doi:10.1212/WNL.0000000000009724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。